Asuragen to Present at World CB & CDx Europe Summit in London, UK
Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that its senior vice president of commercial operations, Colin Hill, will chair a roundtable discussion during the 2018 World Clinical Biomarkers & Companion Diagnostic (CB & CDx) Europe Summit taking place May 1-3 in London, UK. The session will focus on the imminent changes to the regulatory environment in Europe and the implications for pharmaceutical and diagnostic companies collaborating to advance precision medicine.
“Precision medicine is becoming a reality around the world, and the regulations that guide it are rapidly evolving,” said Hill. “It is essential that we build close collaboration between the pharmaceutical, medical device and in vitro diagnostics industry if we are going to successfully navigate this new environment. While our success will definitely leverage learnings from the US experience, we will have to broaden our thinking as we deal with some of the inherent differences in the healthcare delivery model(s) between the US and Europe.”
The roundtable discussion, titled “The Rx-Dx Paradigm and Ensuring Continued CDx Development with Appropriate Risk and Reward,” is part of the Drug-Dx Commercialisation Stream and will occur at 16.30 on Wednesday, May 2. The discussion will highlight several topical issues facing both the pharmaceutical and diagnostic industries, including addressing value share imbalances between these industries, streamlining the collaboration process from concept to commercialization, and understanding the specific nuances of the European market to ensure mutual successes.
Asuragen is a molecular diagnostic company changing the way patients are treated in genetics and oncology. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. For more information, visit www.asuragen.com .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-MOODY’S20.8.2018 23:08 | pressemeddelelse
Moody’s Completes Acquisition of Omega Performance
PACIFIC-DRILLING20.8.2018 16:04 | pressemeddelelse
Pacific Drilling Announces Settlement in Mediation Between Quantum Pacific and Ad Hoc Group of Creditors
CA-TRUE-RELIGION20.8.2018 14:34 | pressemeddelelse
Bella Hadid Headlines True Religion’s Latest Campaign
MA-VERISTAT20.8.2018 13:32 | pressemeddelelse
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™ (patisiran)
FRISS20.8.2018 13:32 | pressemeddelelse
FRISS Brings Claim Fraud Analysis to a Next Level With Web-IQ´s Innovative Online Network Solution
IBC20.8.2018 13:20 | pressemeddelelse
Global IBC Future Zone and IABM Future Trends Theatre to Explore the Latest Tech Shaping the Industry
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum